3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
3
Phase 3
1
Status
Completed
2
Terminated
1
Sponsor Class
OTHER
2
INDUSTRY
1
Study Type
Interventional
3
Sponsor
Cancer Type
Breast
3
Conditions
Breast Neoplasms
163
Endometrial Neoplasms
13
Ovarian Neoplasms
12
Fallopian Tube Neoplasms
5
Recurrence
4
Neoplasms
4
Neoplasm Metastasis
4
Carcinoma, Intraductal, Noninfiltrating
4
Triple Negative Breast Neoplasms
3
Breast Diseases
3
Breast Cancer Metastatic
3
Prostatic Neoplasms
2
Leiomyosarcoma
2
Carcinoma, Lobular
2
Advanced Breast Cancer
2
Uterine Neoplasms
1
Uterine Cervical Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Solid Tumor
1
Small Cell Lung Carcinoma
1
Polycystic Ovary Syndrome
1
Pathologic Complete Response
1
Pancreatic Neoplasms
1
Pain
1
Osteoporosis
1
Neoplastic Cells, Circulating
1
Neoadjuvant Operable Breast Cancer
1
Multiple Endocrine Neoplasia Type 1
1
Medullary cystic kidney disease 1
1
Lymphangioleiomyomatosis
1
Interventions
Fulvestrant
5
Letrozole
3
Capecitabine
3
ribociclib
2
exemestane
2
dalpiciclib
2
apatinib
2
Irinotecan
2
Gemcitabine
2
Anastrozole
2
tusamitamab ravtansine
1
trastuzumab deruxtecan
1
sacituzumab govitecan
1
pegfilgrastim
1
palbociclib
1
margetuximab
1
irinotecan sucrosofate
1
fluzoparib
1
abemaciclib
1
Vinorelbine
1
Trastuzumab
1
Tamoxifen
1
Paclitaxel
1
Liposomes
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
3 trials
Recent
Start date
Enrollment
Phase 2
×
Breast Cancer Metastatic
×
Letrozole
×
Clear all
NCT04059484
2026-02-24
AMEERA-3
Sanofi
Phase 2
Terminated
367 enrolled
30 charts
NCT04603183
2025-12-12
ABIGAIL
MedSIR
Phase 2
Completed
162 enrolled
NCT03555877
2023-07-07
AMICA
GBG Forschungs GmbH
Phase 2
Completed
56 enrolled